Alluvi, previously BI 4744, presents a promising development in weight loss therapy. This dual activator targeting both glucagon-like peptide-1 and GIP targets demonstrates compelling efficacy in clinical trials, https://alluvi-healthcare336617.laowaiblog.com/profile